BioXcel Free Cash Flow Yield vs Cash Per Share Analysis

BTAI Stock

USD 0.44 0.04 8.33%

BioXcel Therapeutics financial indicator trend analysis is way more than just evaluating BioXcel Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioXcel Therapeutics is a good investment. Please check the relationship between BioXcel Therapeutics Free Cash Flow Yield and its Cash Per Share accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.

Free Cash Flow Yield vs Cash Per Share

Free Cash Flow Yield vs Cash Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioXcel Therapeutics Free Cash Flow Yield account and Cash Per Share. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between BioXcel Therapeutics' Free Cash Flow Yield and Cash Per Share is -0.15. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Cash Per Share in the same time period over historical financial statements of BioXcel Therapeutics, assuming nothing else is changed. The correlation between historical values of BioXcel Therapeutics' Free Cash Flow Yield and Cash Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of BioXcel Therapeutics are associated (or correlated) with its Cash Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash Per Share has no effect on the direction of Free Cash Flow Yield i.e., BioXcel Therapeutics' Free Cash Flow Yield and Cash Per Share go up and down completely randomly.

Correlation Coefficient

-0.15

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Cash Per Share

Most indicators from BioXcel Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioXcel Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.The BioXcel Therapeutics' current Selling General Administrative is estimated to increase to about 66.7 M, while Issuance Of Capital Stock is projected to decrease to under 21.1 M.

BioXcel Therapeutics fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Property Plant Equipment	Other Current Liab	Net Tangible Assets	Property Plant And Equipment Net	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Other Current Assets	Property Plant And Equipment Gross	Common Stock	Short Long Term Debt Total	Net Debt	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital	Short Long Term Debt
Total Assets		0.72	0.79	0.81	0.81	0.46	1.0	0.64	0.8	0.93	0.88	0.54	0.9	0.65	0.9	0.89	0.68	0.37	-0.84	0.34	1.0	0.83	0.79	0.74	0.98	-0.13
Total Current Liabilities	0.72		0.14	0.9	0.96	0.94	0.72	0.64	0.93	0.59	0.73	0.95	0.65	0.31	0.85	0.84	0.73	0.9	-0.23	-0.06	0.73	0.91	0.96	0.74	0.59	-0.62
Total Stockholder Equity	0.79	0.14		0.38	0.3	-0.19	0.79	0.41	0.34	0.79	0.65	-0.07	0.73	0.68	0.52	0.54	0.37	-0.28	-1.0	0.48	0.77	0.4	0.27	0.46	0.88	0.4
Common Stock Shares Outstanding	0.81	0.9	0.38		0.92	0.75	0.81	0.71	0.91	0.75	0.81	0.82	0.77	0.49	0.88	0.91	0.82	0.69	-0.46	0.0	0.8	0.95	0.91	0.83	0.74	-0.4
Other Stockholder Equity	0.81	0.96	0.3	0.92		0.85	0.81	0.65	0.88	0.77	0.79	0.91	0.76	0.44	0.88	0.89	0.73	0.81	-0.38	-0.02	0.83	0.95	1.0	0.75	0.7	-0.63
Total Liab	0.46	0.94	-0.19	0.75	0.85		0.46	0.44	0.81	0.33	0.48	0.96	0.37	0.06	0.68	0.63	0.55	1.0	0.1	-0.15	0.48	0.76	0.86	0.54	0.31	-0.75
Total Current Assets	1.0	0.72	0.79	0.81	0.81	0.46		0.64	0.8	0.93	0.88	0.54	0.89	0.65	0.9	0.88	0.68	0.38	-0.84	0.35	1.0	0.83	0.79	0.74	0.98	-0.13
Property Plant Equipment	0.64	0.64	0.41	0.71	0.65	0.44	0.64		0.62	0.63	0.92	0.63	0.74	0.33	0.7	0.89	0.75	0.37	-0.46	-0.06	0.63	0.77	0.64	0.86	0.6	-0.23
Other Current Liab	0.8	0.93	0.34	0.91	0.88	0.81	0.8	0.62		0.62	0.73	0.8	0.7	0.45	0.88	0.85	0.7	0.76	-0.42	0.1	0.79	0.9	0.87	0.75	0.73	-0.31
Net Tangible Assets	0.93	0.59	0.79	0.75	0.77	0.33	0.93	0.63	0.62		0.86	0.48	0.89	0.65	0.8	0.84	0.66	0.25	-0.83	0.24	0.93	0.8	0.76	0.73	0.93	-0.2
Property Plant And Equipment Net	0.88	0.73	0.65	0.81	0.79	0.48	0.88	0.92	0.73	0.86		0.64	0.88	0.49	0.88	0.97	0.77	0.4	-0.7	0.18	0.88	0.86	0.78	0.85	0.85	-0.23
Accounts Payable	0.54	0.95	-0.07	0.82	0.91	0.96	0.54	0.63	0.8	0.48	0.64		0.52	0.14	0.74	0.76	0.68	0.94	-0.02	-0.21	0.56	0.85	0.92	0.68	0.39	-0.79
Non Current Assets Total	0.9	0.65	0.73	0.77	0.76	0.37	0.89	0.74	0.7	0.89	0.88	0.52		0.83	0.72	0.88	0.69	0.28	-0.78	0.0	0.9	0.79	0.74	0.71	0.88	-0.16
Non Currrent Assets Other	0.65	0.31	0.68	0.49	0.44	0.06	0.65	0.33	0.45	0.65	0.49	0.14	0.83		0.33	0.51	0.37	-0.01	-0.7	-0.15	0.64	0.47	0.42	0.36	0.68	0.11
Other Current Assets	0.9	0.85	0.52	0.88	0.88	0.68	0.9	0.7	0.88	0.8	0.88	0.74	0.72	0.33		0.92	0.71	0.62	-0.59	0.39	0.89	0.9	0.87	0.79	0.85	-0.29
Property Plant And Equipment Gross	0.89	0.84	0.54	0.91	0.89	0.63	0.88	0.89	0.85	0.84	0.97	0.76	0.88	0.51	0.92		0.79	0.56	-0.61	0.09	0.88	0.95	0.88	0.88	0.83	-0.32
Common Stock	0.68	0.73	0.37	0.82	0.73	0.55	0.68	0.75	0.7	0.66	0.77	0.68	0.69	0.37	0.71	0.79		0.49	-0.43	-0.08	0.69	0.79	0.72	0.86	0.62	-0.36
Short Long Term Debt Total	0.37	0.9	-0.28	0.69	0.81	1.0	0.38	0.37	0.76	0.25	0.4	0.94	0.28	-0.01	0.62	0.56	0.49		0.19	-0.17	0.4	0.7	0.82	0.47	0.22	-0.78
Net Debt	-0.84	-0.23	-1.0	-0.46	-0.38	0.1	-0.84	-0.46	-0.42	-0.83	-0.7	-0.02	-0.78	-0.7	-0.59	-0.61	-0.43	0.19		-0.47	-0.82	-0.48	-0.36	-0.52	-0.92	-0.34
Other Assets	0.34	-0.06	0.48	0.0	-0.02	-0.15	0.35	-0.06	0.1	0.24	0.18	-0.21	0.0	-0.15	0.39	0.09	-0.08	-0.17	-0.47		0.32	-0.02	-0.04	-0.06	0.41	0.39
Cash And Short Term Investments	1.0	0.73	0.77	0.8	0.83	0.48	1.0	0.63	0.79	0.93	0.88	0.56	0.9	0.64	0.89	0.88	0.69	0.4	-0.82	0.32		0.82	0.81	0.73	0.97	-0.19
Common Stock Total Equity	0.83	0.91	0.4	0.95	0.95	0.76	0.83	0.77	0.9	0.8	0.86	0.85	0.79	0.47	0.9	0.95	0.79	0.7	-0.48	-0.02	0.82		0.94	0.9	0.76	-0.43
Capital Surpluse	0.79	0.96	0.27	0.91	1.0	0.86	0.79	0.64	0.87	0.76	0.78	0.92	0.74	0.42	0.87	0.88	0.72	0.82	-0.36	-0.04	0.81	0.94		0.74	0.68	-0.65
Deferred Long Term Liab	0.74	0.74	0.46	0.83	0.75	0.54	0.74	0.86	0.75	0.73	0.85	0.68	0.71	0.36	0.79	0.88	0.86	0.47	-0.52	-0.06	0.73	0.9	0.74		0.7	-0.24
Net Invested Capital	0.98	0.59	0.88	0.74	0.7	0.31	0.98	0.6	0.73	0.93	0.85	0.39	0.88	0.68	0.85	0.83	0.62	0.22	-0.92	0.41	0.97	0.76	0.68	0.7		0.03
Short Long Term Debt	-0.13	-0.62	0.4	-0.4	-0.63	-0.75	-0.13	-0.23	-0.31	-0.2	-0.23	-0.79	-0.16	0.11	-0.29	-0.32	-0.36	-0.78	-0.34	0.39	-0.19	-0.43	-0.65	-0.24	0.03

Click cells to compare fundamentals

BioXcel Therapeutics Account Relationship Matchups

BioXcel Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	36.4M	219.9M	239.4M	205.9M	73.7M	100.3M
Total Current Liabilities	8.5M	11.8M	16.7M	32.9M	27.3M	28.6M
Total Stockholder Equity	26.9M	206.7M	221.7M	76.8M	(56.5M)	(53.7M)
Common Stock Shares Outstanding	16.3M	21.7M	26.4M	28.0M	29.1M	21.5M
Other Stockholder Equity	83.6M	345.5M	467.4M	488.3M	534.1M	560.8M
Total Liab	9.5M	13.2M	17.8M	129.1M	130.2M	136.7M
Total Current Assets	34.1M	217.1M	233.0M	202.9M	72.1M	98.2M
Property Plant Equipment	2.2M	1.3M	1.3M	1.1M	1.2M	855.5K
Other Current Liab	3.5M	6.9M	11.4M	22.3M	13.2M	8.5M
Net Tangible Assets	26.9M	206.7M	221.7M	76.8M	88.3M	89.5M
Property Plant And Equipment Net	2.2M	2.8M	2.5M	2.1M	1.5M	1.6M
Retained Earnings	(56.7M)	(138.9M)	(245.8M)	(411.5M)	(590.6M)	(561.1M)
Accounts Payable	5.0M	4.0M	4.7M	10.2M	13.7M	14.3M
Cash	32.4M	213.1M	233.0M	193.7M	65.2M	107.4M
Non Current Assets Total	2.3M	2.9M	6.5M	3.0M	1.6M	2.3M
Liabilities And Stockholders Equity	36.4M	219.9M	239.4M	205.9M	73.7M	112.8M
Non Current Liabilities Total	1.0M	1.4M	1.1M	96.2M	102.9M	108.1M
Other Current Assets	1.7M	6.9M	3.8M	6.9M	4.9M	3.4M
Property Plant And Equipment Gross	2.2M	2.8M	3.1M	2.9M	2.7M	1.9M
Common Stock	16K	18K	24K	28K	30K	31.5K
Net Debt	(31.4M)	(211.5M)	(231.6M)	(99.6M)	36.2M	38.0M
Cash And Short Term Investments	32.4M	213.1M	233.0M	193.7M	65.2M	122.7M
Common Stock Total Equity	16K	18K	24K	28K	32.2K	22.7K
Capital Surpluse	83.6M	345.5M	467.4M	488.3M	561.5M	589.6M
Net Invested Capital	26.9M	206.7M	221.7M	169.8M	44.1M	41.9M
Net Working Capital	25.6M	205.2M	220.1M	170.0M	44.9M	42.6M
Retained Earnings Total Equity	(56.7M)	(138.9M)	(245.8M)	(411.5M)	(370.4M)	(351.9M)

Currently Active Assets on Macroaxis

C	Citigroup
GM	General Motors
F	Ford Motor
GM	General Motors
V	Visa Class A

When determining whether BioXcel Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioXcel Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioxcel Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioxcel Therapeutics Stock:

How To Invest In BioXcel

Details

Is BioXcel Stock a good investment?

Details

What is BioXcel Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.

You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.04)

Revenue Per Share

0.074

Quarterly Revenue Growth

1.416

Return On Assets

(0.64)

Return On Equity

(17.67)

The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioXcel Free Cash Flow Yield vs Cash Per Share Analysis

Free Cash Flow Yield vs Cash Per Share

Free Cash Flow Yield vs Cash Per Share Correlation Analysis

Correlation Coefficient

Free Cash Flow Yield

Cash Per Share

BioXcel Therapeutics fundamental ratios Correlations

BioXcel Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioXcel Therapeutics fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Capital Surpluse	+ 1.0	Other Stockholder Equity
Short Long Term Debt Total	+ 1.0	Total Liab
Cash And Short Term Investments	+ 1.0	Total Current Assets
Net Invested Capital	+ 0.98	Total Assets

Net Debt	- 1.0	Total Stockholder Equity
Net Invested Capital	- 0.92	Net Debt
Net Debt	- 0.84	Total Current Assets
Net Debt	- 0.84	Total Assets
Net Debt	- 0.83	Net Tangible Assets
Cash And Short Term Investments	- 0.82	Net Debt